Daniel Habermehl

List of Publications by Year
in descending order

63 papers	2,013 citations	172386 29 h-index	254106 43 g-index
64 all docs	64 docs citations	64 times ranked	2667 citing authors

#	Article	IF	Citations
1	Incidental dose distribution to locoregional lymph nodes of breast cancer patients undergoing adjuvant radiotherapy with tomotherapy - is it time to adjust current contouring guidelines to the radiation technique?. Radiation Oncology, 2019, 14, 135.	1.2	11
2	Neoadjuvant image-guided helical intensity modulated radiotherapy of extremity sarcomas â€“ a single center experience. Radiation Oncology, 2019, 14, 2.	1.2	14
3	Neoadjuvant versus definitive chemoradiation in patients with squamous cell carcinoma of the esophagus. Radiation Oncology, 2019, 14, 66.	1.2	9
4	Dosimetric quantification of the incidental irradiation of the â€˜trueâ€™ (deep) ano-inguinal lymphatic drainage of anal cancer patients not described in conventional contouring guidelines. Acta OncolÃ³gica, 2018, 57, 825-830.	0.8	6
5	Clinical outcome after particle therapy for meningiomas of the skull base: toxicity and local control in patients treated with active rasterscanning. Radiation Oncology, 2018, 13, 54.	1.2	37
6	Perioperative chemotherapy vs. neoadjuvant chemoradiation inÂgastroesophageal junction adenocarcinoma. Strahlentherapie Und Onkologie, 2018, 194, 125-135.	1.0	13
7	Dosimetric comparison of different radiation techniques (IMRT vs. 3-dimensional) of the â€œtrueâ€•(deep) ano-inguinal lymphatic drainage of anal cancer patients. Radiation Oncology, 2018, 13, 227.	1.2	2
8	Impact of VMAT-IMRT compared to 3D conformal radiotherapy on anal sphincter dose distribution in neoadjuvant chemoradiation of rectal cancer. Radiation Oncology, 2018, 13, 237.	1.2	20
9	Dosimetric analysis and comparison of reduced longitudinal cranial margins of VMAT-IMRT of rectal cancer. Radiation Oncology, 2018, 13, 169.	1.2	3
10	MicroRNA expression profiling for the prediction of resistance to neoadjuvant radiochemotherapy in squamous cell carcinoma of the esophagus. Journal of Translational Medicine, 2018, 16, 109.	1.8	34
11	Evaluation of the tumor movement and the reproducibility of two different immobilization setups for image-guided stereotactic body radiotherapy of liver tumors. Radiation Oncology, 2018, 13, 15.	1.2	3
12	Evaluation of particle radiotherapy for the re-irradiation of recurrent intracranial meningioma. Radiation Oncology, 2018, 13, 86.	1.2	35
13	Comparison of definite chemoradiation therapy with carboplatin/paclitaxel or cisplatin/5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiation Oncology, 2018, 13, 139.	1.2	23
14	Volumetric response of intracranial meningioma after photon or particle irradiation. Acta OncolÃ³gica, 2017, 56, 431-437.	0.8	14
15	Neoadjuvant chemoradiation is highly effective and leads to high R0 resection rates and higher pCR rates than perioperative chemotherapy protocols with a comparable impact on distant metastasis. Journal of Surgical Oncology, 2017, 115, 501-503.	0.8	0
16	Primary radio(chemo)therapy for esophageal cancer in elderly patients: are efficiency and toxicity comparable with younger patients?. European Journal of Medical Research, 2017, 22, 24.	0.9	8
17	Combination of Photon and Carbon Ion Irradiation with Targeted Therapy Substances Temsirolimus and Gemcitabine in Hepatocellular Carcinoma Cell Lines. Frontiers in Oncology, 2017, 7, 35.	1.3	7
18	Comparative Analysis of Efficacy, Toxicity, and Patient-Reported Outcomes in Rectal Cancer Patients Undergoing Preoperative 3D Conformal Radiotherapy or VMAT. Frontiers in Oncology, 2017, 7, 225.	1.3	9

#	Article	IF	Citations
19	Comparison of neoadjuvant chemoradiation with carboplatin/ paclitaxel or cisplatin/ 5-fluoruracil in patients with squamous cell carcinoma of the esophagus. Radiation Oncology, 2017, 12, 182.	1.2	20
20	First intraindividual comparison of contrast-enhanced MRI, FET- and DOTATOC- PET in patients with intracranial meningiomas. Radiation Oncology, 2017, 12, 169.	1.2	12
21	Effective radiotherapeutic treatment intensification in patients with pancreatic cancer: higher doses alone, higher RBE or both?. Radiation Oncology, 2017, 12, 203.	1.2	9
22	Comparison of dosimetric parameters and toxicity in esophageal cancer patients undergoing 3DÂconformal radiotherapy or VMAT. Strahlentherapie Und Onkologie, 2016, 192, 722-729.	1.0	27
23	Metabolic liver function after stereotactic body radiation therapy for hepatocellular carcinoma. Acta OncolÃ³gica, 2016, 55, 886-891.	0.8	16
24	Changes in Gross Tumor Volume and Organ Motion Analysis During Neoadjuvant Radiochemotherapy in Patients With Locally Advanced Pancreatic Cancer Using an In-House Analysis System. Technology in Cancer Research and Treatment, 2016, 15, 348-354.	0.8	4
25	Optimization of Carbon Ion Treatment Plans by Integrating Tissue Specific Î±/Î²-Values for Patients with Non-Resectable Pancreatic Cancer. PLoS ONE, 2016, 11, e0164473.	1.1	5
26	Evaluation of inter- and intrafractional motion of liver tumors using interstitial markers and implantable electromagnetic radiotransmitters in the context of image-guided radiotherapy (IGRT) â€“ the ESMERALDA trial. Radiation Oncology, 2015, 10, 143.	1.2	11
27	Optimization of carbon ion and proton treatment plans using the raster-scanning technique for patients with unresectable pancreatic cancer. Radiation Oncology, 2015, 10, 237.	1.2	15
28	Radiation-induced motility alterations in medulloblastoma cells. Journal of Radiation Research, 2015, 56, 430-436.	0.8	14
29	Reirradiation Using Carbon Ions in Patients with Locally Recurrent Rectal Cancer at HIT: First Results. Annals of Surgical Oncology, 2015, 22, 2068-2074.	0.7	50
30	Adjuvant radiotherapy and chemoradiation with gemcitabine after R1 resection in patients with pancreatic adenocarcinoma. World Journal of Surgical Oncology, 2015, 13, 149.	0.8	3
31	The Relative Biological Effectiveness for Carbon and Oxygen Ion Beams Using the Raster-Scanning Technique in Hepatocellular Carcinoma Cell Lines. PLoS ONE, 2014, 9, e113591.	1.1	34
32	Photon-induced cell migration and integrin expression promoted by DNA integration of HPV16 genome. Strahlentherapie Und Onkologie, 2014, 190, 944-949.	1.0	1
33	Palliative radiation therapy in patients with metastasized pancreatic cancer - description of a rare patient group. European Journal of Medical Research, 2014, 19, 24.	0.9	12
34	Prognostic Impact of CA 19-9 on Outcome after Neoadjuvant Chemoradiation in Patients with Locally Advanced Pancreatic Cancer. Annals of Surgical Oncology, 2014, 21, 2801-2807.	0.7	31
35	Four-Dimensional Patient Dose Reconstruction for Scanned Ion Beam Therapy of Moving Liver Tumors. International Journal of Radiation Oncology Biology Physics, 2014, 89, 175-181.	0.4	43
36	Evaluation of chemoradiotherapy with carbon ions and the influence of p53 mutational status in the colorectal carcinoma cell line HCT 116. Tumori, 2014, 100, 675-84.	0.6	6

#	Article	IF	Citations
37	Single-dose radiosurgical treatment for hepatic metastases - therapeutic outcome of 138 treated lesions from a single institution. Radiation Oncology, 2013, 8, 175.	1.2	41
38	Development and validation of automatic tools for interactive recurrence analysis in radiation therapy: optimization of treatment algorithms for locally advanced pancreatic cancer. Radiation Oncology, 2013, 8, 138.	1.2	10
39	Hypofractionated carbon ion therapy delivered with scanned ion beams for patients with hepatocellular carcinoma â€“ feasibility and clinical response. Radiation Oncology, 2013, 8, 59.	1.2	70
40	Chemoradiation in patients with isolated recurrent pancreatic cancer - therapeutical efficacy and probability of re-resection. Radiation Oncology, 2013, 8, 27.	1.2	46
41	Hearing preservation after radiotherapy for vestibular schwannomas is comparable to hearing deterioration in healthy adults and is accompanied by local tumor control and a highly preserved quality of life (QOL) as patientsâ€™ self-reported outcome. Radiotherapy and Oncology, 2013, 106, 175-180.	0.3	40
42	Phase I study evaluating the treatment of patients with locally advanced pancreatic cancer with carbon ion radiotherapy: the PHOENIX-01 trial. BMC Cancer, 2013, 13, 419.	1.1	22
43	Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy. Radiotherapy and Oncology, 2013, 109, 487-492.	0.3	74
44	Skull base meningiomas: Long-term results and patient self-reported outcome in 507 patients treated with fractionated stereotactic radiotherapy (FSRT) or intensity modulated radiotherapy (IMRT). Radiotherapy and Oncology, 2013, 106, 186-191.	0.3	108
45	Proton and carbon ion radiotherapy for primary brain tumors and tumors of the skull base. Acta OncolÃ³gica, 2013, 52, 1504-1509.	0.8	55
46	Prospective evaluation of early treatment outcome in patients with meningiomas treated with particle therapy based on target volume definition with MRI and ⁶⁸Ga-DOTATOC-PET. Acta OncolÃ³gica, 2013, 52, 514-520.	0.8	68
47	Evaluation of different fiducial markers for image-guided radiotherapy and particle therapy. Journal of Radiation Research, 2013, 54, i61-i68.	0.8	79
48	In vitro evaluation of photon and raster-scanned carbon ion radiotherapy in combination with gemcitabine in pancreatic cancer cell lines. Journal of Radiation Research, 2013, 54, i113-i119.	0.8	36
49	Carbon Ion Irradiation Inhibits Glioma Cell Migration Through Downregulation of Integrin Expression. International Journal of Radiation Oncology Biology Physics, 2012, 83, 394-399.	0.4	42
50	Long-Term Outcome After Radiotherapy in Patients With Atypical and Malignant Meningiomasâ€”Clinical Results in 85 Patients Treated in a Single Institution Leading to Optimized Guidelines for Early Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2012, 83, 859-864.	0.4	128
51	Phase I/II trial evaluating carbon ion radiotherapy for the treatment of recurrent rectal cancer: the PANDORA-01 trial. BMC Cancer, 2012, 12, 137.	1.1	46
52	Connection of European particle therapy centers and generation of a common particle database system within the European ULICE-framework. Radiation Oncology, 2012, 7, 115.	1.2	11
53	Comparison of intensity modulated radiotherapy (IMRT) with intensity modulated particle therapy (IMPT) using fixed beams or an ion gantry for the treatment of patients with skull base meningiomas. Radiation Oncology, 2012, 7, 44.	1.2	37
54	Proton and carbon ion radiotherapy for primary brain tumors delivered with active raster scanning at the Heidelberg Ion Therapy Center (HIT): early treatment results and study concepts. Radiation Oncology, 2012, 7, 41.	1.2	46

#	Article	IF	Citations
55	Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiation Oncology, 2012, 7, 28.	1.2	86
56	Early Treatment Response of a Rare Papillary Tumor of the Pineal Region after Primary Proton-Beam Therapy using the Raster-Scanning Technique at HIT. Tumori, 2012, 98, e122-e125.	0.6	3
57	Assessment of Early Toxicity and Response in Patients Treated With Proton and Carbon Ion Therapy at the Heidelberg Ion Therapy Center Using the Raster Scanning Technique. International Journal of Radiation Oncology Biology Physics, 2011, 81, e793-e801.	0.4	39
58	Phase i study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: The PROMETHEUS-01 trial. BMC Cancer, 2011, 11, 67.	1.1	37
59	Targeting Î±Î½Î²3 and Î±Î½Î²5 inhibits photon-induced hypermigration of malignant glioma cells. Radiation Oncology, 2011, 6, 132.	1.2	28
60	Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: The CLEOPATRA Trial. BMC Cancer, 2010, 10, 478.	1.1	83
61	Randomised phase I/II study to evaluate carbon ion radiotherapy versus fractionated stereotactic radiotherapy in patients with recurrent or progressive gliomas: The CINDERELLA trial. BMC Cancer, 2010, 10, 533.	1.1	75
62	Treatment of patients with atypical meningiomas Simpson grade 4 and 5 with a carbon ion boost in combination with postoperative photon radiotherapy: The MARCIE Trial. BMC Cancer, 2010, 10, 615.	1.1	48
63	Heidelberg Ion Therapy Center (HIT): Initial clinical experience in the first 80 patients. Acta OncolÃ³gica, 2010, 49, 1132-1140.	0.8	93